Tyrosine kinase inhibitorFDA-approvedSecond-line

Mekinist

Generic name: trametinib

How it works

Blocks the MEK pathway, a signaling pathway that drives cancer cell growth, allowing the cancer cells to die.

Cancer types

Melanoma— BRAF V600E-positive

Efficacy

In clinical trials, around 50% of patients achieved an objective response, with a median progression-free survival of approximately 4.8 months.

Side effects

Moderate

Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.

Evidence from research

Study	Cancer type	Stage	Efficacy
Comparing Treatments for Melanoma Patients	Melanoma	meta-analysis	Dabrafenib and trametinib improved recurrence-free survival (RFS) compared to anti-PD(L)1 therapies (hazard ratio [HR] 0.53, 95% CI, 0.40-0.70, P < .01).	Source →

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.